Molecular biology

DGAP-News: CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

Tuesday, July 27, 2021 - 1:07pm

CEVEC also announced that the ELEVECTA(R) Technology is currently being implemented in HEK293 as a second host cell type.

Key Points: 
  • CEVEC also announced that the ELEVECTA(R) Technology is currently being implemented in HEK293 as a second host cell type.
  • As HEK293 is the most widely used host cell line in gene therapy manufacturing, CEVEC expects to see a significant increase in demand from clients and partners.
  • "We are delighted to be part of this financing round with the aim of accelerating the company's growth and becoming market leader for stable vector manufacturing technologies in cell and gene therapies."
  • The company's product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins.

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Monday, July 26, 2021 - 12:05pm

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2021 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, The Netherlands, July 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2021 and highlighted recent progress across its business.
  • In accordance with the agreement, the upfront payment of $450 million was paid to uniQure on May 7, 2021.
  • In June 2021, the Company announced the first two patient procedures were completed in the second dose cohort of Phase I/II clinical trial.
  • In June, the Company announced the planned acquisition of Corlieve Therapeutics, a pre-clinical gene therapy company based in France.

Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Acidemia

Monday, July 26, 2021 - 1:00pm

WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of world renowned AAV gene therapy pioneer Jude Samulski, Ph.D., as a special advisor to assist with the development of their gene therapy programs. Additionally, Selecta has published a peer-reviewed online article describing pre-clinical data from its study investigating the efficacy of co-administration of ImmTOR™ nanoparticles with AAV vectors in transgene expression in methylmalonic acidemia (MMA) in the journal Molecular Therapy Methods & Clinical Development. The publication, entitled, “ImmTOR nanoparticles enhance AAV-driven transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia,” was led by Petr Ilyinskii, Ph.D., a senior director at Selecta.

Key Points: 
  • Overcoming immunogenicity is a huge challenge for the entire gene therapy field, said Dr. Samulski.
  • The preclinical data presented in this study supports Selectas ImmTOR technology potential to be a game-changing technology.
  • Dr. Samulski is professor of pharmacology and has been the director of the University of North Carolina Gene Therapy Center for over two decades.
  • Repeated administration of AAV vectors enabled by ImmTOR resulted in increased vector transduction and further decreases in plasma methylmalonic acid that was dose dependent.

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

Monday, July 26, 2021 - 9:01pm

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005727/en/

Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Monday, July 26, 2021 - 1:24pm

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021.
  • An audio replay will be available in the Investors section of the companys website.
  • Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times.
  • Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs.

NuProbe Announces New Research and New Product on DNA Microsatellite Instability

Monday, July 26, 2021 - 5:00pm

Simultaneously, the company announced the release of the VarTrace MSI qPCR research use only assay for detection of DNA microsatellite instability (MSI) from tissue or blood specimens.

Key Points: 
  • Simultaneously, the company announced the release of the VarTrace MSI qPCR research use only assay for detection of DNA microsatellite instability (MSI) from tissue or blood specimens.
  • By constructing and experimentally validating a thermodynamic model of DNA microsatellite binding, NuProbe scientists overcame the challenges associated with MSI detection.
  • "The NuProbe VarTrace MSI qPCR assay allows qPCR-based detection of MSI from tumor tissue and cell-free DNA," said Alessandro Pinto, Ph.D., Associate Director of Product at NuProbe USA.
  • This allows the NuProbe product to be applied to cell-free DNA from peripheral blood plasma as well as to formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

$5.5+ Billion Global Sequencing Reagents Market to 2028 - by Technology, Application, Reagent Type, End-user and Geography - ResearchAndMarkets.com

Friday, July 23, 2021 - 11:14am

The "Sequencing Reagents Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Technology; Application; Reagent Type; End User; Geography."

Key Points: 
  • The "Sequencing Reagents Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Technology; Application; Reagent Type; End User; Geography."
  • The global sequencing reagents market is expected to reach US$ 14,195.60 million by 2028 from US$ 5,530.32 million in 2020; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028.
  • The factors such as growing funding for genomics, declining cost of sequencing procedures, and increasing prevalence of chronic diseases drive the market growth.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

Thursday, July 22, 2021 - 2:24pm

Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.

Key Points: 
  • Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.
  • "We're excited to share our overall 264 test results from our Brazilian AcuVid Saliva / RT-PCR Test Clinical Study.
  • The additional 201 test results, on top of the initial 63, not only exceed FDA-EUA minimum requirements, but confirms the performance quality and ease-of-use of our AcuVid saliva test.
  • In fact, our complete AcuVid study achieved comparable, and in some cases, better performance results than other leading COVID-19 rapid antigen tests available on today's market," expressed Rob Fia, CEO of Therma Bright.

Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums

Thursday, July 22, 2021 - 5:45pm

For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.

Key Points: 
  • For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.
  • Now the FDA has released guidance to BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) for its T-cell immune response diagnostic platform CoviDTH to begin Phase I/II Clinicial Trials.
  • However, later in July, Abbott was reported to be working to import the PanBio Covid-19 self tests from Korea.
  • The Sofia test was the first rapid antigen test to get an FDA greenlight , back in May of last year.

Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums

Thursday, July 22, 2021 - 5:45pm

VANCOUVER, B.C., July 22, 2021 /PRNewswire/ -- USA News Group  -  Two of the world's most prominent billionaires, George Soros and Bill Gates, recently made headlines backing a consortium to buy UK Covid-19 test maker Mologic for $41 million ahead of a new initiative of a global rollout for rapid result testing. As demand shifts, newer innovations from not only from Mologic are gaining attention, including a new T-Cell Immune Response diagnostic from BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), antigen tests from Abbott Laboratories (NYSE: ABT), Chembio Diagnostics, Inc. (NASDAQ: CEMI) and Quidel Corporation (NASDAQ: QDEL), and antibody tests from Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX).

Key Points: 
  • For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.
  • Now the FDA has released guidance to BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) for its T-cell immune response diagnostic platform CoviDTH to begin Phase I/II Clinicial Trials.
  • However, later in July, Abbott was reported to be working to import the PanBio Covid-19 self tests from Korea.
  • The Sofia test was the first rapid antigen test to get an FDA greenlight , back in May of last year.